A representative case of paclitaxel-coated balloon treatment in a de novo lesion. by Soe Hee Ann (775368)

“…The plaque phenotype, fibroatheroma remain unchanged and the plaque burden (PB) decreased over time (I; 66%, J; 50%, K; 47%, L: 40%). …”

High-fat diet-fed <i>MK2^−/−</i> mice have reduced adipose tissue expression of the insulin-responsive glucose transporter GLUT4. by Jan Freark de Boer (631340)

Former Abusers of Anabolic Androgenic Steroids Exhibit Decreased Testosterone Levels and Hypogonadal Symptoms Years after Cessation: A Case-Control Study by Jon Jarløv Rasmussen (2993427)

“…</p><p>Methods</p><p>This study had a cross-sectional case-control design and involved 37 current AAS abusers, 33 former AAS abusers (mean (95%CI) elapsed duration since AAS cessation: 2.5 (1.7; 3.7) years) and 30 healthy control participants. …”

Cumulative distribution of EQ-5D-3L utilities decreasingly ordered before and after the onset of cutaneous leishmaniasis symptoms. by Janaína de Pina Carvalho (12152812)

Annual number of outpatient visits in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

“…<p>In the recurrence group, mean outpatient visits (± standard deviation) decreased from 13.6 ± 3.0 to 11.9 ± 5.0, 8.1 ± 3.9, and 7.8 ± 3.2 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”

Annual treatment frequencies in all eyes. by Yasuyuki Sotani (20114144)

“…<p>The number of anti-VEGF treatments, STTA, MA-PC, PPV, and total treatments (mean ± SD) significantly decreased from 2.6 ± 1.6, 0.3 ± 0.8, 0.6 ± 0.8, 0.1 ± 0.3, and 3.7 ± 1.7 preoperatively to 0.8 ± 1.9, 0.0 ± 0.2, 0.3 ± 1.0, 0.0, and 1.2 ± 2.2; at year 2 to 0.7 ± 2.0, 0.1 ± 0.6, 0.0 ± 0.2, 0.0 ± 0.2, and 1.0 ± 2.1; and at year 3 to 0.9 ± 2.2, 0.0, 0.2 ± 1.0, 0.0 ± 0.2, and 1.1 ± 3.1 (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”

Annual number of outpatient visits in all eyes. by Yasuyuki Sotani (20114144)

“…<p>Mean visit frequency (mean ± standard deviation) significantly decreased from 11.5 ± 4.3 preoperatively to 8.8 ± 4.1, 5.0 ± 3.4, and 4.4 ± 3.2 visits in the first, second, and third postoperative years, respectively (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”

Immune challenge increases the intensity of some Ni-Sp185/333 proteins and decreases the intensity of others. by Lauren S. Sherman (800584)

Annual treatment frequencies in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

“…Mean outpatient visits in the recurrence group decreased from 13.6 ± 3.0 to 11.9 ± 5.0, 8.1 ± 3.9, and 7.8 ± 3.2 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, p < 0.001). …”

KOR-agonist (U50'488) and MOR-agonist (DAMGO) decrease symptoms in OVA-allergic mice. by Swantje C. Duncker (154707)

Ethanol withdrawal affects behavior in the light/dark test and decreases convulsive thresholds in zebrafish by Suianny Nayara da Silva Chaves (3118641)

Relative Aggrecan mRNA expression levels, as measured by qPCR, in lentiviral-transduced control cells and 5 AggKD cell lines confirm decreased Aggrecan expression in the AggKD cell... by Juanita K. Hodax (6848540)

Influence of ghrelin treatment (0.5 μg/g BW, twice a day, intraperitoneal (ip.)) on survival, body weight and body temperature within 48 hours after cecal ligation and puncture (CL... by Daniel Siegl (717509)

A new and improved algorithm for the quantification of chromatin condensation from microscopic data shows decreased chromatin condensation in regenerating axolotl limb cells by Julian Sosnik (3704914)

Comparison between mean-field solutions and simulations on networks. by Valeria d’Andrea (12095838)

<i>Trans ε</i> viniferin decreases amyloid deposits and inflammation in a mouse transgenic Alzheimer model by Martial Caillaud (6383672)

“…Here, effects of this stilbenoid were evaluated in transgenic APPswePS1dE9 mice. We report that <i>trans ε</i>-viniferin could go through the blood brain barrier, reduces size and density of amyloid deposits and decreases reactivity of astrocytes and microglia, after a weekly intraperitoneal injection at 10 mg/kg from 3 to 6 months of age.…”

The minimum inhibitory concentrations (µg/mL) and the minimum bactericidal concentrations (µg/mL) of synthesized 1,2,3,5-tetrazine derivatives. by Jean Paul Dzoyem (6424445)

Subjects:

Percentages of inhibition of biofilm formation and eradication of synthesized 1,2,3,5-tetrazine derivatives. by Jean Paul Dzoyem (6424445)

Subjects:

Reactions’ sequences to compounds 4. by Jean Paul Dzoyem (6424445)

Subjects:

Percentage of violacein production in <i>Chromobacterium violaceum</i> by the most active synthesized 1,2,3,5-tetrazine derivatives (4a, 4b and 4c). by Jean Paul Dzoyem (6424445)

Subjects: